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Abstract| Molecular, genetic and pathological evidence suggests that deficits in GABAergic 
parvalbumin-positive interneurons contribute to schizophrenia pathophysiology through 
alterations in the brain’s excitation-inhibition balance that result in impaired behaviour and 
cognition. Although the factors that trigger these deficits are diverse, there is increasing 
evidence that they converge on a common pathological hub that involves NMDA receptor 
hypofunction and oxidative stress. These factors have been separately linked to 
schizophrenia pathogenesis, but evidence now suggests they are mechanistically 
interdependent and contribute to common schizophrenia-associated pathology. 
  
 
 
Schizophrenia is a psychiatric disorder that affects 1% of the population, with typical onset at 
late adolescence and early adulthood. Current treatments, which primarily induce D(2) 
dopamine receptor (DRD2) blockade, are most effective for the positive symptoms of 
schizophrenia (such as hallucinations or delusions) but have little effect on the negative 
symptoms (such as flattening affect or social withdrawal) or cognitive deficits (such as 
impaired memory, attention, and executive functions) and have major side effects.  
 The development of more effective schizophrenia treatments requires a better 
understanding of disease aetiology and the underlying mechanisms of what is a multi-
factorial disorder. Both human epidemiological and animal model studies point to genetic and 
environmental factors that affect critical periods in early and adolescent brain development 
and that take place in advance of symptoms 1. Pathologically, many diverse causes of 
schizophrenia and schizophrenia-like behaviours appear to converge on a similar deficit: the 
aberrant function of fast-spiking parvalbumin-positive interneurons (PVIs) 2, which leads to 
altered excitation-inhibition balance 3 . Together with myelination defects 4, this may account 
for the emergence of schizophrenia pathophysiology and symptoms in early adulthood. The 
relatively long period over which adverse genetic and environmental factors integrate to 
cause schizophrenia, coupled with the existence of a clear prodromal phase, points to a 
therapeutic opportunity that mechanistic insight into schizophrenia causation may allow 
clinicians to exploit. 
 In this Perspective article, we summarize recent research that suggests that diverse 
causes of schizophrenia converge on a pathological hub that is centred on two 
interdependent factors: brain redox imbalance and NMDA receptor (NMDAR) hypofunction. 
We describe evidence that this pathological hub, when activated during development, might 
lead to some of the key hallmarks of schilzophrenia, including defects in PVIs and in the 
Neuroinﬂammation
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function of their associated networks, as well as high frequency neuronal synchrony 2, 5. We 
also discuss the clinical studies that will be required to prove or disprove this hypothesis and 
to determine which therapeutic strategies may prove effective in targeting this pathological 
hub both before and after diagnosis. 
 
NMDAR dysfunction in schizophrenia 
NMDARs (N-methyl-D-aspartate (NMDA) receptors) are glutamate-gated cation-passing 
channels that play a key role in the CNS. They are permeant to Ca2+, which mediates many 
of the consequences of NMDAR activity, including synaptic modification, learning and 
memory, activity-dependent development, and neuroprotective/homeostatic signaling 6-8. 
 
Human studies suggest NMDAR hypofunction 
The hypothesis that NMDAR hypofunction might be a pathogenic trigger for schizophrenia 9, 
10 arose from observations that administration of the dissociative anesthetics phencyclidine 
and ketamine to healthy subjects mimicked the primary symptoms of schizophrenia 11, 12 
coupled with the finding that these compounds are NMDAR antagonists 13. Recently, 
autoimmune diseases associated with anti-NMDAR antibodies were reported to be 
associated with severe psychosis 14. Subsequent behavioral, neurophysiological and 
functional imaging studies have supported the NMDAR hypofunction hypothesis of 
schizophrenia,  showing that  indicators of sensory dysfunction in patients with schizophrenia 
— such as mismatch negativity (MMN) and changes in auditory and visual event-related 
potentials — can be mimicked by treating otherwise healthy individuals with NMDAR 
antagonists 12, 15. Post-mortem studies of the brain of patients with schizophrenia have 
revealed lower levels of expression of the obligate NMDAR subunit GRIN1 (glutamate 
receptor ionotropic, NMDA 1), increases in the expression of the endogenous NMDAR 
antagonist kynurenate, and a reduction in levels of the NMDAR co-agonist D-serine and the 
enzyme that catalyses its production, D-serine racemase 10, 16-18. An NMDAR single-photon 
emission computed tomography (SPECT) study pointed to lower NMDAR activity  in 
unmedicated patients with schizophrenia 19, although this finding awaits confirmation with 
newer, more specific probes 20. Proton magnetic resonance spectroscopy (MRS studies) 
revealed hyperglutamatergic activity in patients with schizophrenia and groups at high risk of 
developing schizophrenia, which may be attributable to NMDAR hypofunction 20. 
 Genetic evidence also points to disturbed NMDAR signaling in schizophrenia. A 
recent genome-wide association study (GWAS) implicated serine racemase (SRR) and 
GRIN2A as risk genes for schizophrenia 21 as well as other genes functionally up- and down-
stream of NMDAR activity 21, 22. Exome sequencing has revealed schizophrenia-linked de 
novo mutations in GRIN2A and GRIN2B [Tarabeux, 2011 #3386;Myers, 2011 #3486] which 
CN
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is consistent with a growing number of NMDAR subunit mutations associated with 
neurodevelopmental disorders (Figure 1).  
 
NMDAR hypofunction in animal models 
As in humans, treatment of adult rodents with NMDAR antagonists triggers acute 
schizophrenia-related behaviours, including deficits in attention and/ or vigilance, learning 
and memory and sensory gating, broadly mimicking the symptoms of patients with 
schizophrenia 10, 15, 23, 24. Genetically-modified mouse models of NMDA hypofunction — 
including the Grin1 hypomorphic mouse 25 and the Srr knockout mouse 26 — have also 
revealed schizophrenia-relevant phenotypes and neurochemical deficits. 
 
Specific vulnerability to NMDAR hypofunction 
The existence of prenatal risk factors for schizophrenia, such as maternal infections, 
nutritional deficiency, obstetrical complications and stress, suggests that there is a 
developmental window of sensitivity in which a transient early insult leads to long-lasting 
developmental perturbations 1. In supporting of this notion, NMDAR antagonism during an 
equivalent period in rodents (first 2 post-natal weeks) induces long-lasting behavioural and 
cognitive disturbances that are relevant to the schizophrenia phenotype and which extend 
into adolescence and adulthood 10, 27. Moreover, severe NMDAR blockade induces forebrain 
apoptosis in rats, but only when administered between the first and third postnatal week 28. A 
milder antagonism regime caused long-lasting behavioural changes and a specific long-
lasting decrease in cortical PVI numbers 29, mimicking a key pathological feature of 
schizophrenia 2. 
 Genetic models also support the notion of the developmental sensitivity of PVIs to 
NMDAR hypofunction. Early post-natal, but not adolescent, deletion of Grin1 in mouse  
forebrain interneurons reduced their expression of parvalbumin and glutamate decarboxylase 
1 (GAD1, also known as GAD67), and caused cortical disinhibition and asynchrony 30, 31. This 
interneuron-specific deletion was sufficient to induce schizophrenia-relevant phenotypes after 
adolescence, including novelty-induced hyperlocomotion, deficits in mating and nest-building 
and anxiety-like behaviors 30, as well as spatial memory impairment 31. The behavioural 
deficits induced by interneuronal Grin1 deletion are exacerbated by social isolation stress30, 
which models aspects of known environmental risks for schizophrenia, including childhood 
maltreatment and psychosocial adverse events 1. 
 Thus, studies suggest that aberrant NMDAR function during development particularly 
affects PVIs and that these effects are sufficient to induce long-lasting delayed behavioural 
and cognitive abnormalities in the adult. 
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Redox imbalance in schizophrenia 
Oxidative stress, is defined as an imbalance between levels of prooxidants and antioxidants 
and is known to result in macromolecular damage and the activation of redox-sensitive 
signals. The maintenance of redox balance in the brain is challenging due to its high lipid 
content and metabolic rate, as well as the non-regenerative nature of CNS neurons 32-34. 
During development, even subtle peturbations to redox balance can affect the signaling 
pathways and processes involved in neurogenesis and neuronal differentiation 35.  
 The antioxidant systems employed to neutralise reactive oxygen species (ROS) and 
reverse oxidative damage in the brain have been reviewed comprehensively elsewhere 32, 34. 
These systems function to maintain redox balance by supplying reducing equivalents 
(electrons) to electrophilic xenobiotics, ROS and proteins. As described below, the 
antioxidant glutathione (GSH) has special relevance to schizophrenia pathophysiology 
(Figure 2). 
 
Human studies of redox imbalance  
Evidence for oxidative stress has been found in patients with schizophrenia, including 
increased lipid and protein oxidation in blood, cerebrospinal fluid (CSF) and post-mortem 
tissue 36, 37, as well as altered levels of plasma antioxidants (such as vitamins C and E, 
catalase, GSH and GSH-peroxidase) 36, 38 and CSF superoxide dismutase-1 levels 39. 
Proteomic postmortem studies also point to the activation of oxidative stress responses in 
schizophrenia 40. In particular, GSH system deficits have been linked to schizophrenia 
pathophysiology in several ways. GSH levels have been shown to be lower in chronic 
schizophrenia, as measured in the CSF and post-mortem brain, and by MRS-based in vivo 
imaging 41, 42 and the GSH system enzymes glutathione peroxidase (GPX) and glutathione 
reductase (GR) are also dysregulated 36. Importantly, low cortical GSH levels have been 
found to correlate with more severe negative symptoms in patients with schizophrenia 43. 
 Genetic evidence also points to a role for GSH system deficits in schizophrenia 
etiopathogeny. An allelic variant of the GCLC gene, which encodes the catalytic subunit of 
GSH biosynthetic enzyme glutamate-cysteine ligase (GCL) is associated with schizophrenia. 
This polymorphism is associated with reduced induction of GSH, GCL activity, and GCLC 
expression in schizophrenia patient-derived fibroblasts 44. Evidence that copy number 
variants and polymorphisms within glutathione-s-transferase (GST) genes may be 
susceptibility factors for schizophrenia has also been revealed 45. 
 
Animal studies of redox imbalance 
Animal studies suggest that brain GSH deficits and oxidative stress are sufficient to induce 
schizophrenia-like behaviour. Mice deficient in the GCL regulatory subunit Gclm have 
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reduced brain GSH levels and exhibit schizophrenia-relevant behavioural and cognitive 
deficits, including altered stress responses, amphetamine responses, social behaviour, 
prepulse inhibition (PPI) and learning 46, 47,. Pharmacological depletion of brain GSH using a 
GCL inhibitor induces similar sensory and cognitive disturbances 48, 49. 
 Investigations of the biological roles of known schizophrenia risk genes such as 
dystrobrevin binding protein 1 (DTNBP1, dysbindin-1), proline dehydrogenase 1 (PRODH), 
neuregulin 1 (NRG1), D-amino acid oxidase activator (DAOA, also known as G72) and 
disrupted in schizophrenia 1 (DISC1) also suggest that oxidative stress may be involved in 
schizophrenia etiopathogeny. For example, DTNBP1  forms a complex that interacts with 
peroxiredoxins 1 and 2 50, key CNS antioxidant proteins 33, and DTNBP1 is itself degraded by 
oxidative stress  51. PRODH is a mitochondrial flavoenzyme that metabolizes proline and is 
essential for the antioxidant effects of proline 52. NRG1–ERBB4 signalling is involved in ROS-
induced neuronal differentiation 53. Proteomic analysis of the brains of mice transgenic for the 
primate specific G72 gene revealed perturbations associated with oxidative stress, 
mitochondrial dysfunction and white matter deficits 54. Oxidative stress is also observed in a 
mouse expressing a dominant negative form of DISC1 55. The causal relevance of oxidative 
stress was further strengthened by the demonstration that juvenile antioxidant treatment 
using N-Acetyl cysteine (NAC) prevents oxidative stress in a developmental rat model of 
schizophrenia (neonatal ventral hippocampal lesion (NVHL)) and, in doing so, inhibits the 
emergence of morphological, electrophysiological and behavioural deficits 56. Cognitive 
deficits in the G72 transgenic mouse were also rescued by NAC therapy 57. 
 
Specific vulnerability to oxidative stress 
PVIs are highly sensitive to redox status and ROS signalling. For example, neuron-specific 
reduction of the levels of selenoproteins (a group of proteins that include several 
antioxidants) selectively impaired PVI development 58, which was also observed in the 
prefrontal and ventral hippocampal regions in Gclm-deficient mice 46, 59, 60. Targeted deletion 
of Gclc in PVIs triggers oxidative stress, impairs their development and causes a delay and 
prolongation in the critical period of cortical plasticity resulting in a failure to stabilise cortical 
circuits 61. Moreover, adult mice in which Gclc was deleted specifically in PVIs exhibit 
impaired contralateral bias index following monocular deprivation, indicative of long-lasting 
defects 61. 
 The vulnerability of PVI function to oxidative stress is high early in development, 
resulting in permanent consequences for the adult: in Gclm-deficient mice, oxidative 
challenges at juvenile and peripubertal ages, but not in the adult, lead to long-lasting PVI 
impairments in the prefrontal cortex (PFC) 59, 60. Moreover, transient pharmacological 
depletion of brain GSH early in development (between postnatal days 5 and 16) leads to PVI 
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abnormalities in the adult anterior cingulate cortex as well as cognitive and olfactory 
discrimination deficits 49. Transient developmental disruption of DISC1 signaling using an 
inducible and reversible transgenic model results in defects in plasticity in the adult cortex 62. 
Given that disrupting DISC1 signalling induces oxidative stress and reduces PVI 
immunoreactivity 55, 63, it is tempting to speculate that oxidative stress is a contributor to these 
observed defects. Evidence causally linking oxidative stress to PVI deficits in other 
schizophrenia models also exists: NAC treatment prevents PVI abnormalities in the NVHL 
model 56 and blocking superoxide overproduction by NADPH oxidase (NOX) prevents the 
PVI impairment induced by social isolation 64.  
 Mechanistically, PVI deficits after oxidative stress could be due to loss of ensheathing 
perineuronal nets (PNN)-networks of extracellular matrix, which play a protective role against 
oxidative stress and yet are vulnerable themselves to ROS 60 . Moreover, the high intrinsic 
spiking rate of PVIs, with its attendant metabolic demands and ROS production, may place 
particular demands on their antioxidant defences. One outstanding issue is the mechanism 
by which oxidative stress results in the long-lasting reduction of GAD and PV expression and 
whether this reflects the activation of specific ROS-activated signals such as dopamine 
metabolites, or is simply the result of a global defect in development due to non-specific 
oxidative damage. It is also important to note that white matter deficits are another 
schizophrenia-relevant pathology influenced by oxidative stress in development 65. A 
correlation exists between PFC GSH levels and white matter integrity in the cingulum bundle 
in both control and early psychosis patients, which may reflect the role of GSH in controlling 
oligodendrocyte progenitor proliferation and differentiation 66. 
 To conclude, several schizophrenia models provide evidence of oxidative stress that 
preferentially induces PVI deficits. Moreover, development stage- or PVI-specific oxidative 
stress is sufficient to induce long-lasting behavioural and cognitive abnormalities in the adult. 
 
Making the link 
There are clear similarities between the impact of developmental NMDAR hypofunction and 
that of oxidative stress on the adult rodent: both cause a selective impairment in PVI function 
and similar behavioural and cognitive disturbances. Indeed, increasing evidence suggests 
that NMDAR hypofunction and redox imbalance may be reciprocally linked (Figure 3). 
 The NMDAR is regulated by redox state: both GRIN1 and GRIN2A possess pairs of 
redox-sensitive cysteine residues whose disulfide bond formation decreases NMDAR 
currents 67, 68, while an overlapping group of cysteine residues are subject to inhibitory S-
nitrosylation which facilitates disulfide bond formation 67. Redox regulation is particularly 
strong for GRIN2A-containing NMDARs, where a region of the N-terminus is sufficient to 
mediate the potentiation of currents by reducing agents such as Dithiothreitol  or GSH 68, 69. 
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Of note, even transient GSH deficits are sufficient to induce NMDAR hypofunction 70. 
Recently it has been shown that changes in intracellular redox status can also modulate 
NMDAR activity in a manner that is relevant to age-dependent cognitive decline 71, 72. Age-
associated shifts in intracellular redox state to a pro-oxidizing environment have been linked 
to reduced NMDAR activity via the redox regulation of calcium/ calmodulin-dependent protein 
kinase type II (CaMKII), and can be rescued by intracellular GSH 72. Thus, the redox balance 
of the brain, acting in no small part via GSH, controls NMDAR activity. 
 Critically, there is also a reciprocal relationship: NMDAR hypofunction itself leads to 
cortical oxidative stress and GSH defcits 73, 74. At the cellular level, synaptic NMDAR activity 
enhances the capacity of both the glutathione system and thioredoxin/peroxiredoxin system 
(another important antioxidant pathway in the brain 75) through the transcriptional control of 
several key antioxidant genes 73, 76, 77 (Figure. 4). Of note, the GSH deficit induced by 
NMDAR blockade in the developing mouse is associated with transcriptional downregulation 
of Gclc and reduced GCL activity, which contributes to the deleterious effects observed in 
vivo 77. Moreover, GABAergic interneuron-specific deletion of Grin1 has been show to lead to 
increased ROS levels which are exacerbated by post-weaning social isolation, in association 
with down-regulation of peroxisome proliferative activated  receptor-γ, coactivator 1α 
(PPARGC1A, also known as PGC-1α), a regulator of mitochondrial energy metabolism and 
antioxidant defences 78. The functional benefits of the coupling of synaptic NMDAR activity to 
the control of antioxidant defences are still a matter of speculation, although it may be an 
adaptive mechanism to tune neuronal antioxidant defences to the elevated needs of an 
electrically and metabolically active neuron. Thus, NMDAR hypofunction may uncouple 
synaptic activity from the regulation of antioxidant systems. 
 NMDAR hypofunction also contributes to oxidative stress through its circuit-level 
effects. NMDAR antagonism likely induces a hyperglutamatergic state by reducing the 
activity of cortical interneurons, which particularly rely on NMDARs for their excitatory drive 
early in development 29, 79. Moreover, and as a result, PVI function itself might be 
permanently impaired as a result of relatively mild transient NMDAR hypofunction in the 
developing mouse that does not induce neuronal death  29, 80. The mechanism underlying this 
proposed loss of PVI phenotype involves cortical disinhibition leading to neuronal IL-6 
production and consequent activation of NADPH oxidase, which generates H2O2 29. One can 
envisage that both circuit and cellular-level effects could combine to exacerbate oxidative 
stress (Figure 3).  
 The weaker intrinsic antioxidant defences of neurons as compared to other brain cells 
such as astrocytes 34 may underly their vulnerability to oxidative stress, especially during 
development. Indeed, they express little nuclear factor erythroid 2-related factor 2 (NFE2L2, 
also known as NRF2), a transcription factor and master regulator of antioxidant defence 
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genes 81, 82 (Figure 5). NFE2L2 is epigenetically repressed in cortical neurons early in 
development and what little NFE2L2 exists is highly unstable, leading to reduced intrinsic 
antioxidant defences 81, 83. Weakened defences appear to be necessary to activate redox-
sensitive neuronal maturation pathways 81. However, this deprives neurons of a useful 
adaptive response, since NFE2L2-dependent gene expression is activated by mild oxidative 
stress 82, 84, 85. Interestingly, many of the antioxidant genes transcriptionally controlled by 
synaptic activity in neurons are known NFE2L2 target genes, but are induced via NFE2L2-
independent routes (e.g. via activator protein 1 (AP-1) family and activating transcription 
factor 4 (ATF4)), suggesting that activity-dependent signaling may act as a substitute for an 
absent NFE2L2 pathway 73, 86, 87. Moreover, a recent study has shown that persistent 
activation of astrocytic NMDARs can activate NFE2L2-dependent gene expression, raising 
the possibility that synaptic activity can control the NFE2L2 pathway in astrocytes 83. 
 Another consequence of relatively weak intrinsic antioxidant defences is that neurons 
rely on astrocytes to provide extrinsic support 82. In response to oxidative stress, astrocytes 
increase GSH production (via NFE2L2-dependent mechanisms) and release. The release 
GSH is broken down and used for neuronal GSH production (Figure 5). The vulnerability of 
cortical neurons to oxidative stress and NMDAR hypofunction early in development could be 
due to the relatively low number of astrocytes at this stage, coupled with the high metabolic 
demands of rapid synaptogenesis. Regardless, the interdependence of NMDAR 
hypofunction and oxidative stress in development means that different genetic and 
environmental factors can potentially converge on a similar pathological outcome underlying 
schizophrenia-like phenotypes (Figure 3). 
 
Interactions with neuroinflammation  
Considerable evidence implicates neuroinflammation in the etiology of schizophrenia 88. 
Epidemiological evidence points to maternal infection being a risk factor in schizophrenia 1 
and maternal infection in mice is sufficient to induce long-term PPI and social behavioural 
changes in the offspring, changes that are attributable to inflammation 89. Inflammation is 
also likely to be an aggravating factor in the effects of NMDAR hypofunction and oxidative 
stress: prenatal immune challenge by the viral mimetic Polyl:C causes a long-lasting 
sensitivity of the offspring to peri-pubertal stress and NMDAR antagonists 90. Furthermore, 
PVI deficits in the DISC1-dominant negative transgenic mouse are exacerbated by a 
neonatal Polyl:C challenge 91. 
 The deleterious consequences of neuroinflammation may in any case be mediated in 
part by oxidative stress, and so be mechanistically coupled to the oxidative stress-NMDAR 
hypofunction hub of schizophrenia etiology (Figure 3). Activated innate immune cells both 
produce and are activated by ROS: antioxidant therapy with NAC reduces the pathological 
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and behavioural consequences of maternal LPS treatment and reduces foetal pro-
inflammatory cytokine production 92, 93. At the molecular level, the antagonism between 
antioxidant-promoting NFE2L2 and inflammatory gene-regulating NF-κB may control the 
balance between oxidative stress and inflammation 94: disruption of NFE2L2 induces NF-κB 
activation, probably by modifying NF-κB inhibitor α (NFKB1A, also known as IkBα) 
degradation and NF-κB binding to DNA 95, 96  Inversely, NF-κB increases oxidative stress by 
inhibiting NFE2L2 transcription through repression of its creb binding protein (CBP) binding 
and by inducing ARE hypoacetylation 97. Altogether, inflammation and oxidative stress are 
closely interactin and potentiate each other. 
 
Future prospects 
In the coming years, there is hope for the further illumination of schizophrenia etiology, and 
the refining of ideas regarding potential treatments and therapeutic windows. Further human 
data, including patient-based imaging will be important in establishing the role of oxidative 
stress and NMDAR hypofunction (plus any links between them) in schizophrenia. In 
particular, longitudinal prospective studies of high risk groups will be informative in defining 
features both pre- and post-diagnosis, contrasting with individuals who do not progress to 
schizophrenia. For example, it will be of interest to learn the trajectory of glutamatergic state, 
NMDAR function (using positron emission tomography (PET) ligands) and GSH levels (by 
MRS) and how they link both to clinical symptoms (progression to schizophrenia or not) as 
well as other metrics such as gamma synchrony (by electroencephalography (EEG)) and 
white matter imaging (such as diffusion tensor imaging (DTI)). Moreover, the reverse 
translation of these and other studies will enable preclinical researchers to focus on the key 
pathological triggers and core deficits in schizophrenia, which is apposite since there is no 
single ideal mouse model of schizophrenia. 
 Similar methods will also prove valuable for assessing the efficacy of therapeutic 
interventions, including those aimed at boosting NMDAR function, which have focussed on 
the co-agonist (glycine or D-serine) site as a potential therapeutic target. Indeed, the utility of 
D-serine as a mono- or adjunct therapy for schizophrenia in the prodromal phase remains an 
active area of clinical research 22. A recent trial with clinically high risk patients (scored high 
on the Scale of Prodromal Symptoms (SOPS)) showed that D-serine induced an 
improvement in negative symptoms, a promising result that needs to be confirmed in a larger 
cohort 98. Unfortunately, a glycine transporter antagonist recently failed in Phase III trials; 
however, it is important to note that which of glycine or D-serine act on the NMDAR may 
depend on activation conditions 99 and modulating them may therefore not give equivalent 
results. Being able to monitor NMDAR function with specific PET ligands may provide 
information on the likely efficacy of these and other treatments that directly or indirectly 
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influence NMDAR function, and allow therapies to be tuned to avoid NMDAR-mediated 
neurotoxicity. Indeed co-administration of antioxidants may also help to mitigate such 
adverse effects. 
 Antioxidant therapies have the potential to reduce oxidative stress and in doing so 
reduce NMDAR hypofunction 100 and inflammation. NAC, which upon deacetylation provides 
cells with the limiting amino acid for GSH biosynthesis, is a well-tolerated compound and the 
focus of several published and ongoing clinical studies. Published studies have revealed 
beneficial effects in schizophrenia patients as an add-on to maintenance medication 100-103 
and ongoing studies are following up their results and including additional metrics of efficacy 
such as brain GSH imaging in order to reflect the BBB permeability analyses of NAC that 
have been performed in rodents 104. The therapeutic window for antioxidant therapy remains 
an open question. For example, intervention shortly after, or even before diagnosis, may 
rescue or limit PVI deficits that are irreversible in the patient with chronic schizophrenia. The 
potential for juvenile NAC treatment to prevent the emergence of electrophysiological and 
behavioural deficits in a rodent developmental model of schizophrenia 56 suggests that 
prophylactic treatment for high-risk groups may be effective, particularly with a drug or 
dietary supplement with a good safety profile like NAC or polyunsaturated fatty acids such as 
omega 3s 105. 
 Nevertheless, NAC may not represent an optimal antioxidant therapy, since its 
principal modus operandus — the supply of increased cysteine for GSH biosynthesis — is of 
limited help unless the brain can use it to produce, recycle and utilise GSH. A more holistic 
approach to rebalancing the brain's redox status may be to target the NFE2L2 pathway, 
which regulates dozens (if not hundreds) of genes controlling antioxidant and detoxification 
processes (Figure 5). Several NFE2L2-activating compounds have efficacy in preclinical 
models of neurodegenerative disease 82 and one, sulforaphane, has shown some promise in 
a preliminary open-label trial for SZ 106. Moreover, BG-12 (also known as Tecfidera or 
dimethyl fumarate) is licensed for the relapsing remitting phase of multiple sclerosis and has 
cytoprotective and anti-inflammatory actions attributable to NFE2L2 activation 107. This may 
therefore be a promising candidate for schizophrenia antioxidant therapy. It is important to 
note that even though NFE2L2 is only weakly activatable in neurons 81, 83, NFE2L2 activators 
promote neuronal resistance to oxidative stress via non cell-autonomous mechanisms 
involving NF22L2 activation in astrocytes, including human astrocytes 82, 108 
 To conclude, multiple strands of evidence indicate that NMDAR hypofunction and 
oxidative imbalance are a pathological hub in schizophrenia etiology upon which several 
genetic and environmental influences converge. The coming years will tell us whether this 
extra knowledge can be converted to effective symptomatic, preventive or disease-modifying 
therapies. 
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Figure Legends 
 
Figure 1. Human GRIN2 mutations associated with neurodevelopmental and 
psychiatric disorders. Schematic showing the locations of GRIN2A (glutamate receptor 
ionotropic NMDA 2a) and GRIN2B heterozygous missense mutations identified in people 
with neurodevelopmental disorders. The extreme extracellular N-terminus of these subunits 
contains allosteric modulation sites. The region between the N-terminus and the M1 domain, 
plus the extracellular loop between the M3 and M4 domains encode the glutamate-binding 
domain. The M2 domain features many sidechains that point towards the receptor channel 
pore and dictate ion permeability. Finally, the long cytoplasmic C-terminal domain is involved 
in receptor targeting and coupling to downstream signaling complexes. It is important to note 
that schizophrenia-associated mutations tend to be located at the N- and C-termini, away 
from the ligand binding and pore-forming regions. Mutations in the ligand binding and pore 
regions are predicted to be more fundamentally disruptive and tend to be more associated 
with childhood-onset intellectual disability and global delay (and often with epilepsy), as are 
nonsense or frameshift mutations in any domain 109. This suggests that schizophrenia-
associated NMDA receptor hypofunction may be either milder or more temporally or spatially 
restricted than that caused by genome-level subunit ablation. Figure based on data in 
references110-118. [Au: correct? Are there any other references that should be cited 
here?] [Au: in these images does each dash in the extracellular domain represent an 
amino acid or are they approximations of the size of each region?]. 
 
Figure 2. Key functions of the glutathione antioxidant system. Reduced glutathione 
(GSH) facilitates the transfer of reducing equivalents (species which transfer the equivalent 
of one electron) via NADPH generated by the pentose phosphate pathway of glucose 
metabolism, to a range of end points (red arrows). This transfer facilitates the reduction of 
cellular peroxides, catalysed by glutathione peroxidases (GPX), as well as the reduction of 
protein thiol groups, catalysed by glutaredoxins (Grx). GSH plays a key role in the 
neutralization of electrophilic xenobiotic compounds, becoming conjugated to them in a 
reaction catalysed by glutathione-s-transferases (Gst). Glutathione reductase (Gr) catalyses 
the reduction of oxidized glutathione (GSSG) back to GSH, using NADPH as a cofactor. Also 
shown are two sources of cellular peroxide: superoxide dismutation by SOD, monoamine 
oxidase metabolism of dopamine, and Nadph oxidase (NOX). Collectively, the GSH and 
GSH system enzymes play a key role in cellular redox homeostasis. X+: electrophilic 
xenobiotic; GS-X: GSH conjugated to xenobiotic;  Grx-S2 (oxidized) and Grx-(SH)2,(reduced) 
glutaredoxin; ROOH: organic peroxide; ROH: organic hydroxide. 
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Figure 3. Reciprocal links between NMDA receptor (NMDAR) hypofunction and 
oxidative stress. NMDAR hypofunction triggers both cellular effects (the downregulation of 
antioxidant genes) and circuit level disinhibition of cortical networks that leads to reactive 
oxygen species (ROS) generation through activation of NADPH oxidase (NOX). Both of 
these events have the capacity to lead to oxidative stress and glutathione (GSH) depletion, 
which in turn can further repress NMDAR activity. The consequences of oxidative stress and 
GSH deficits during development can include impaired development and maturation of 
parvablumin-expressing interneurons (PVIs, leading to excitation/inhibition (E/I) imbalance) 
and white matter abnormalities, which collectively may lead to altered cognition, behaviour 
and sensory processing in schizophrenia. Key external factors may also influence this 
pathological hub: neuroinflammation can act both up- and down-stream of ROS and 
inflammatory cytokine (such as interleukin-6 (IL6)) production. Mitochondrial dysfunction can 
also be both up-and down-stream of oxidative stress. Moreover, environmental and genetic 
factors have the capacity to influence NMDAR function, antioxidant defences, and 
inflammation. 
 
Figure 4. Synaptic activity boosts the capacity of neuronal antioxidant systems. 
Schematic shows the changes in antioxidant system gene expression induced by synaptic 
activity. Transcriptionally induced genes are targeted by red arrows, repressed genes by red 
lines ended in flat bars. The capacity of neurons to produce, utilize, and recycle glutathione 
(GSH) is enhanced by synaptic activity. Activity-dependent induction of GCLC, which 
encodes the catalytic subunit of GCL (glutamate-cysteine ligase), increases the capacity of 
the rate-limiting step in GSH biosynthesis, whereas the induction of glutathione reductase 
GR boosts recycling capacity (reducing oxidized GSSG back to GSH). Transcriptional 
induction of glutathione peroxidase (GPX) activity enhances the ability of the GSH system to 
reduce cellular peroxides; however, as a result of increased GR and GCL activity, neuronal 
levels of GSH can be sustained. There are also activity-dependent changes to genes in the 
thioredoxin and/ or peroxiredoxin system. Peroxiredoxins (PRX) catalyse the reduction of 
peroxides, and become oxidized in the process, upon which they are themselves reduced by 
thioredoxin (TRX). Under conditions of excessive peroxide, they can become hyperoxidized, 
and rely on sulfiredoxin (SRXN1) to catalyse the formation of a phospho-ester moiety that 
can be reduced by thioredoxin. Synaptic activity induces expression of Srxn1, and represses 
expression of Txnip, an inhibitor of thioredoxin. (red)=reduced; (ox)=oxidized; 
(ox2)=hyperoxidized. 
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Figure 5. The astrocytic NFE2L2 pathway boosts the brain's antioxidant defences. 
Under normal conditions, Nuclear factor erythroid 2-related factor 2 (NFE2L2) is targeted for 
ubiquitin-mediated degradation by KEAP1 (Kelch-Like ECH-Associated Protein 1). Both 
oxidative stress and certain small molecules (often electrophiles (e.g. tBHQ and BG12) 
interfere with this degradation, enabling NFE2L2 to accumulate, translocate to the nucleus 
and drive the transcription of genes whose promoters contain antioxidant response elements 
(AREs). ARE-containing genes comprise antioxidant genes, and related phase II 
detoxification and/ or xenobiotic conjugation genes (such as glutathione S-transferases) and 
include key components of the glutathione (GSH) and  thioredoxin (TRX) systems. NFE2L2 
activation boosts GSH levels in astrocytes. In response to oxidative stress, this GSH is 
released through the the multidrug resistance protein (MRP1) and broken down to the Cys-
Gly dipeptide by γ-glutamyl transpeptidase (γGT). Cys-Gly, cysteine, cystine or a 
combination thereof are taken up by neurons and used for GSH biosynthesis. By increasing 
the supply of GSH precursors to neurons, the action of astrocytic NFE2L2 is additive and 
complementary to the effects of synaptic NMDA receptor activity in boosting GSH 
biosynthetic capacity 77 (see Figure. 3).  
 
 
 
 
 
 
 
